| Predictors of outcomes of COVID-19 in patients with chronic liver disease: US multi-center study D Kim, N Adeniji, N Latt, S Kumar, PP Bloom, ES Aby, P Perumalswami, ... Clinical Gastroenterology and Hepatology 19 (7), 1469-1479. e19, 2021 | 222 | 2021 |
| Investigation into temperature-induced aggregation of an antibody drug conjugate NS Beckley, KP Lazzareschi, HW Chih, VK Sharma, HL Flores Bioconjugate chemistry 24 (10), 1674-1683, 2013 | 125 | 2013 |
| Liver injury in liver transplant recipients with coronavirus disease 2019 (COVID‐19): US multicenter experience A Rabiee, B Sadowski, N Adeniji, PV Perumalswami, V Nguyen, A Moghe, ... Hepatology 72 (6), 1900-1911, 2020 | 82 | 2020 |
| Glycomics‐based analysis of chicken red blood cells provides insight into the selectivity of the viral agglutination assay U Aich, N Beckley, Z Shriver, R Raman, K Viswanathan, S Hobbie, ... The FEBS journal 278 (10), 1699-1712, 2011 | 48 | 2011 |
| Student engagement in the online classroom: comparing preclinical medical student question‐asking behaviors in a videoconference versus in‐person learning environment JB Caton, S Chung, N Adeniji, J Hom, K Brar, A Gallant, M Bryant, A Hain, ... FASEB BioAdvances 3 (2), 110, 2021 | 47 | 2021 |
| MYC and Twist1 cooperate to drive metastasis by eliciting crosstalk between cancer and innate immunity R Dhanasekaran, V Baylot, M Kim, S Kuruvilla, DI Bellovin, N Adeniji, ... Elife 9, e50731, 2020 | 45 | 2020 |
| Current and emerging tools for hepatocellular carcinoma surveillance N Adeniji, R Dhanasekaran Hepatology communications 5 (12), 1972-1986, 2021 | 35 | 2021 |
| Cathepsin B cleavage of vcMMAE-based antibody–drug conjugate is not drug location or monoclonal antibody carrier specific B Gikanga, NS Adeniji, TW Patapoff, HW Chih, L Yi Bioconjugate chemistry 27 (4), 1040-1049, 2016 | 34 | 2016 |
| Non-alcoholic Fatty Liver Disease and Liver Fibrosis during Aging NJ Li, Y., Adeniji, NT., Fan, W., Kunimoto, K. , Török Aging and Disease, 2022 | 30 | 2022 |
| Isomerization of Asp–Asp motif in model peptides and a monoclonal antibody Fab fragment L Yi, N Beckley, B Gikanga, J Zhang, YJ Wang, HW Chih, VK Sharma Journal of Pharmaceutical Sciences 102 (3), 947-959, 2013 | 30 | 2013 |
| Matrix viscoelasticity promotes liver cancer progression in the pre-cirrhotic liver W Fan, K Adebowale, L Váncza, Y Li, MF Rabbi, K Kunimoto, D Chen, ... Nature 626 (7999), 635-642, 2024 | 28 | 2024 |
| Genomic Landscape of HCC N Adeniji, R Dhanasekaran Current Hepatology Reports, 2020 | 27 | 2020 |
| MYC overexpression drives immune evasion in hepatocellular carcinoma that is reversible through restoration of proinflammatory macrophages R Dhanasekaran, AS Hansen, J Park, L Lemaitre, I Lai, N Adeniji, ... Cancer research 83 (4), 626-640, 2023 | 16 | 2023 |
| Socioeconomic Factors Contribute to the Higher Risk of COVID-19 in Racial and Ethnic Minorities with Chronic Liver Diseases (CLD) DR Adeniji N, Carr RM, Aby ES, Catana AM, Wegermann K Gastroenterology, 2020 | 12* | 2020 |
| Posttransplant Outcomes in Older Patients With Hepatocellular Carcinoma Are Driven by Non–Hepatocellular Carcinoma Factors N Adeniji, V Arjunan, V Prabhakar, A Mannalithara, T Ghaziani, A Ahmed, ... Liver Transplantation 27 (5), 684-698, 2021 | 6 | 2021 |
| Impact of Bridging Locoregional Therapies for Hepatocellular Carcinoma on Post‐transplant Clinical Outcome N Adeniji, V Arjunan, V Prabhakar, Z Tulu, N Kambham, A Ahmed, P Kwo, ... Clinical transplantation 34 (12), e14128, 2020 | 5 | 2020 |
| MYC Overexpression Drives Immune Evasion in Human Cancer that is Reversible Through Restoration of Pro-Inflammatory Macrophages R Dhanasekaran, AS Hansen, J Park, I Lai, N Adeniji, S Kuruvilla, ... bioRxiv, 2022.05. 13.491873, 2022 | 1 | 2022 |
| Multiplatform single cell spatial dissection of the invasive front of hepatocellular carcinoma (HCC) reveals molecular insights into tumor progression J Zhang, N Adeniji, A Suresh, L Lemaitre, V Charu, B Visser, CA Bonham, ... Journal of Hepatology 78, S27-S28, 2023 | | 2023 |
| SPATIAL MULTI-OMIC IMMUNE PROFILING AND FUNCTIONAL CHARACTERIZATION OF HEPATOCELLULAR CARCINOMA (HCC) REVEAL MECHANISMS OF MINIMAL RESIDUAL DISEASE (MRD) A Suresh, N Adeniji, L Lemaitre, V Charu, R Dhanasekaran HEPATOLOGY 76, S1278-S1278, 2022 | | 2022 |
| 326: SPATIAL TRANSCRIPTOMIC CHARACTERIZATION OF HEPATOCELLULAR CARCINOMA (HCC) REVEALS PREDICTIVE BIOMARKERS AND MOLECULAR TARGETS OF RECURRENCE A Suresh, N Adeniji, K Kolahi, N Kambham, V Charu, R Dhanasekaran Gastroenterology 162 (7), S-1123-S-1124, 2022 | | 2022 |
